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Simple Summary: Cardiovascular disease is the leading cause of death worldwide. High blood
cholesterol levels are associated with an increased risk of this condition. How high levels of
blood cholesterol result in cardiovascular disease during aging is a difficult question to answer.
Computational models have been used over the years to help understand this problem, as they are
capable of representing complex systems such as this. The aim of this work was to use a computational
model of cholesterol metabolism to better understand why, in certain studies involving the oldest
old (persons ≥ 85 years), high blood cholesterol levels have been associated with a decreased risk of
death. Using our computational model, we found that key age-associated changes to how cholesterol
is processed in the liver could be responsible for this observation. The findings from our work
contribute to our understanding of cholesterol metabolism in older people and how treatments could
be developed in the future to promote healthy aging.
Abstract: The dysregulation of intracellular cholesterol homeostasis is associated with several
age-related diseases, most notably cardiovascular disease (CVD). Research in this area has benefitted
from using computational modelling to study the inherent complexity associated with the regulation
of this system. In addition to facilitating hypothesis exploration, the utility of modelling lies in its
ability to represent an array of rate limiting enzymatic reactions, together with multiple feedback loops,
which collectively define the dynamics of cholesterol homeostasis. However, to date no model has
specifically investigated the effects aging has on this system. This work addresses this shortcoming by
explicitly focusing on the impact of aging on hepatic intracellular cholesterol homeostasis. The model
was used to investigate the experimental findings that reactive oxygen species induce the total
activation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR). Moreover,
the model explored the impact of an age-related decrease in hepatic acetyl-CoA acetyltransferase 2
(ACAT2). The model suggested that an increase in the activity of HMGCR does not have as significant
an impact on cholesterol homeostasis as a decrease in hepatic ACAT2 activity. According to the model,
a decrease in the activity of hepatic ACAT2 raises free cholesterol (FC) and decreases low-density
lipoprotein cholesterol (LDL-C) levels. Increased acetyl CoA synthesis resulted in a reduction in the
number of hepatic low-density lipoprotein receptors, and increased LDL-C, FC, and cholesterol esters.
The rise in LDL-C was restricted by elevated hepatic FC accumulation. Taken together these findings
have important implications for healthspan. This is because emerging clinical data suggest hepatic
FC accumulation is relevant to the pathogenesis of non-alcoholic fatty liver disease (NAFLD), which
is associated with an increased risk of CVD. These pathophysiological changes could, in part, help to
explain the phenomenon of increased mortality associated with low levels of LDL-C which have been
observed in certain studies involving the oldest old (≥85 years).
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1. Introduction
Cholesterol is an important macronutrient which has several important roles within the body.
It consolidates cell membranes, is the precursor of steroid hormone synthesis, is a prerequisite for
vitamin D synthesis, and is essential to bile acid production [1–5]. However, the dysregulation
of cholesterol metabolism, which leads to hypercholesterolemia, is inexorably associated with the
pathophysiology of several diseases; the most notable being cardiovascular disease (CVD) [6–10].
Elevated plasma cholesterol, particularly low-density lipoprotein cholesterol (LDL-C) is firmly
established as an independent risk factor for atherosclerotic CVD [11,12]. Aging has a pleiotropic effect
on cholesterol metabolism, altering many of the key processes responsible for its regulation [13–21].
It is therefore unsurprising that population studies have shown that LDL-C increases in both males
and females up until the midpoint of life [22–25]. Paradoxically, it has been found in population
studies that LDL-C gradually decreases in the latter decades of life [26–29]. To date, a conclusive
mechanistic explanation for this conundrum remains elusive. However, it is possible this is simply
a survivor effect. Studies in the oldest old (persons ≥ 85 years) also reveal intriguing questions
about cholesterol metabolism and aging. For instance, it has been observed that both high and low
levels of LDL-C can have a similar impact on mortality risk in this population group [30]. This was
revealed despite CVD being the main cause of mortality among this cohort. In light of findings such
as this, others have challenged scientific orthodoxy by suggesting high levels of LDL-C could be
cardioprotective against infections and atherosclerosis [31–34]. However, it is challenging to see how
this is plausible mechanistically. An alternative explanation for these findings could reside within the
biochemical mechanisms which govern hepatic cholesterol homeostasis, and how these processes are
affected by aging [35,36].
The liver is the focal point of cholesterol homeostasis, synthesizing cholesterol and triglycerides
to be incorporated into very low-density lipoproteins (VLDLs) [37]. VLDLs are hydrolysed in the
plasma, by lipoprotein lipase into LDL, via intermediate-density lipoproteins [38]. Circulating LDL-C is
removed by LDL receptors (LDLrs), in a process which is regulated by cellular sterol concentrations [39].
An increase in cellular cholesterol results in the activation of insulin-induced genes (Insigs) proteins,
which bind to sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) in
the endoplasmic reticulum (ER) [40], impeding the transfer of the SCAP/SREBP complex to the Golgi [41].
As the levels of sterol diminish, SREBP-2 is transferred to the Golgi where it is cleaved by subtilisin
kexin isozyme/site-1 protease (SKI-1/S1P) [41,42], and the intramembranous metalloprotease site-2
protease (S2P). This extricates the membrane bound NH-terminal domain of SREBP-2. Two N-terminal
fragments dimerise, then engage with importin-β, prior to their entry into the nucleus, whereby they
induce SREBP-2-regulated gene promoters. This regulatory landscape also includes factors which
control LDLr synthesis. Nuclear SREBP-2 raises the transcription levels of proprotein convertase
subtilisin/kexin type 9 (PCSK9) [43]. PCSK9 reduces the number of LDLr by elevating their metabolism,
and degradation, inhibiting LDL uptake [44]. Elevated intracellular cellular cholesterol levels subdue
SREBP-2 release from the ER, thus PCSK9 transcription is reduced, which raises LDLr levels [45].
The coordinated synergy of SREBP-2-induced transcription of both LDLr and PCSK9 modulates
LDL-C concentration [46]. Moreover, LDL-derived cholesterol provokes hepatic acyl CoA: cholesterol
acyltransferase (ACAT2) [47]. This enzyme catalyses free cholesterol (FC) to cholesterol esters (CE).
In this work, a previously enunciated hypothesis is outlined and examined [35]. It is hoped the
examination of this idea will help to explain why low levels of LDL-C have been associated with
an increased rate of mortality in the oldest old. The premise of the hypothesis is as follows: it has
been found experimentally that a decrease in hepatic cellular antioxidant capacity occurs during
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aging [48,49]. This deficiency opens up an avenue for hepatic reactive oxygen species (ROS) to induce
the total activation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR),
the key rate limiting enzyme in cholesterol biosynthesis [50–54]. Recent experimental findings add
weight to this idea. Seo et al. (2019) found that treating rat HepG2 cells with 500 µM H2O2 led
to a significant increase in SREBP2 and HMGCR [55]. An increase in cholesterol synthesis in turn
elicited a corresponding rise in hepatic FC. This finding resonates with other work of this nature.
For instance, it is important to note that hepatic FC has been observed to significantly rise with
age in rats [56]. In some studies this has been observed to occur side by side with a reduction in
HMGCR levels/activity [57]. Moreover, in certain studies it has been found that there is no difference
between hepatic FC levels in young and old rats [17]. Taking account of these caveats it is possible to
meaningfully speculate that due to a ROS-induced increase hepatic FC and an age-associated decrease
in the activity of cholesterol-esterifying enzyme, ACAT2, there is restricted conversion of excess FC to
CE [58]. However, it must be stressed that there is limited experimental evidence to support a reduction
in ACAT2. The work that does support the notion was conducted using rabbits deficient in LDLrs.
Despite this drawback, for the purposes of our hypothesis, and in line with the discovery-based
exploratory nature of this work, we make the assumption that there is a decrease in hepatic ACAT2.
If this does occur it can be reasonably inferred that the secretion of VLDL-C drops, and there is
a corresponding decrease in LDL-C. As intracellular levels of FC accumulate, this state progresses to
a pathophysiological condition akin to nonalcoholic fatty liver disease (NAFLD) [59]. Due to the strong
association between NAFLD and increased risk of CVD [60], it is possible a deleterious condition akin
to NAFLD, contributes to a pro-inflammatory state, which has the potential to explain why low levels
of LDL-C have been associated with an increased rate of mortality in the oldest old.
Due to its ability to handle the complexities associated with aging and its adeptness at representing
the processes associated with intracellular cholesterol homeostasis, computational systems biology
offers an ideal framework for testing the hypothesis outlined in the previous paragraph [61–74].
Moreover, there is a growing momentum to better understand the aetiology of diseases such as CVD
using computational modelling [75–78]. CVD is underscored by atherosclerosis, an inflammatory
process whereby the LDL-C plays a key role. Due to the complex nature of CVD, there is a biomedical
imperative to use models to help better understand what drives its onset and how cholesterol
modulates this process. A plethora of models of cholesterol metabolism have been assembled
previously [64,65,79–91]. These models have made invaluable contributions to the understanding
of cholesterol metabolism. In particular, the models of Mazein et al. (2013), Watterson et al. (2013),
and Benson et al. (2017), have laid the foundations for modelling the key regulatory processes
which govern cholesterol biosynthesis using a systems biology framework and discipline specific
standards [82,89,90]. Importantly, these models examined the cholesterol biosynthesis pathway and
how its regulatory points can be used as targets for pharmaceutical interventions which help to
maintain cholesterol homeostasis and reduce CVD risk. Other mathematical models have also adopted
a systems biology and discipline-specific standards to conduct work of this nature. Specifically,
they have focused on the intersection between cholesterol metabolism atherosclerosis. These include
Gomez-Cabrero (2011), Parton et al. (2019), and Bekkar et al. (2018) [92–94]. However, to date no model
has specifically investigated the effects aging has on hepatic intracellular cholesterol homeostasis.
This work addresses this shortcoming by developing a model to explicitly focus on the impact of aging
on hepatic intracellular cholesterol homeostasis. This ordinary differential equation (ODE) model
includes the experimental finding that ROS induce the total activation of HMGCR. The model was
then used to explore the effect of aging on hepatic cholesterol biosynthesis.
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2. Materials and Methods
2.1. Network Diagram Construction and Model Assembly
Based on the reaction list in Table 1, a systems biology graphical notation network (SBGN) diagram
was generated to visually capture the model reactions (Figure 1) [95]. SBGN is a framework which has
been developed in order to capture biological networks in a clear and unambiguous manner and it is
supported by a number of software packages [95]. In this case VANTED was used to create this the
SBGN diagram [96] (Supplementary File S1). The add-on SBGN-ED can be used to export the map into
SBGN markup language (SBGN-ML) [97].
A full list of the abbreviations used in Table 1 and Figure 1 is provided in Table S1 of Supplementary
File S2. The model was assembled using the computational systems biology software tool COPASI [28].
COPASI was chosen due to its suitability for modelling systems of this nature, its intuitiveness, and the
fact it is non-commercial software. In addition, COPASI supports the exchange schema systems biology
markup language (SBML), which means the model is straightforward to update and adapt in the future
(Supplementary Files S3 and S4).
The model commences with cholesterol biosynthesis. Firstly, acetyl CoA enters the biosynthesis
pathway. Following this, acetoacetyl CoA thiolase catalyses the interconversion of acetyl CoA
and acetoacetyl CoA. Acetyl CoA and acetoacetyl CoA undergo a condensation reaction to form
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). Following this HMG-CoA is then converted
by HMGCR to mevalonate. Phosphorylation of mevalonate forms mevalonate-5P, which is further
phosphorylated to mevalonate-5PP. Decarboxylation and dehydration of mevalonate-5PP forms
isopentenyl-PP (IPP), which converts to its isoform dimethylallyl-PP (DMAPP). DMAPP reacts with
IPP to create geranyl-PP. Further condensation and the addition of another IPP creates farnesyl-PP.
Condensation of 2 farnesyl-PP molecules forms squalene, which is converted to squalene epoxide
before undergoing cyclisation to form lanosterol. Lanosterol is converted to FC, by a series of reactions.
It is then converted to CE by ACAT2. This reaction is reversible and cholesteryl ester hydrolase (CEH)
converts CE back to FC. The network diagram includes a nominal reaction which represents the
putative effects of ROS on the model HMG-CoA. It also includes antioxidant levels which influence
ROS levels.
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Table 1. List of Model Reactions *.
Reaction Name Abbreviation
R1 Acetyl coenzyme A (CoA) synthesis CoAS→ ACoA
R2 Interconversion of Acetyl CoA and Acetoacetyl CoA ACoA = AACoA
R3 3-hydroxy-3-methylglutaryl (HMG)-CoA formation ACoA + AACoA→ HMGCoA
R4 Mevalonate (MV) formation HMGCoA→MV
R5 Mevalonate5P (MV5P) formation MV→MV5P
R6 Mevalonate5PP (MV5PP) formation MV5P = MV5PP
R7 Isopentenyl-PP (IPP) formation MV5PP→ IPP
R8 Dimethylallyl-PP (DMAPP) interconversion IPP = DMAPP
R9 GeranylPP (GPP) formation DMAPP + IPP→ GPP
R10 FarnesylPP (FPP) formation GPP + IPP→ FPP
R11 Squalene formation FPP→ SQ
R12 Squalene epoxide formation SQ→ SQE
R13 Lanosterol formation SQE→ LAN
R14 Free cholesterol (FC) formation LAN→ FC
R15 Conversion of FC to cholesteryl esters (CE) FC→ CE
R16 Conversion of CE to FC CE→ FC
R17 Cholesterol esters flux to low-density lipoproteincholesterol (LDL-C) CE→ LDLC
R18 LDL-C sink LDLC→ LDLCs
R19 LDL receptor (LDLr) synthesis sLDLR→ LDLR
R20 LDLr degradation LDLR→ dLDLR
R21 Reuptake of LDL-C LDLC→ FC
R22 SREBP synthesis sSRBP2→ SRBP2
R23 SREBP degradation SRBP2→ dSRBP2
R24 Antioxidant production sAOX→ AOX
R25 Reactive oxygen species (ROS) production sROS→ ROS
R26 ROS degradation AOX+ROS→ ROSsink
R27 HMGCoA reductase synthesis sHMGCoAR→ HMGCoAR
R28 HMGCoA reductase degradation HMGCoAR→ dHMGCoAR
R29 Acetyl-CoA acetyltransferase 2 (ACAT2) synthesis sACAT2→ ACAT2
R30 ACAT2 Degradation ACAT2→ dACAT2
* See Table S1 in Supplementary File S2 for abbreviations.
Biology 2020, 9, 314 6 of 18
Biology 2020, 9, x FOR PEER REVIEW 5 of 18 
 
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). Following this HMG-CoA is then converted by 
HMGCR to mevalonate. Phosphorylation of mevalonate forms mevalonate-5P, which is further 
phosphorylated to mevalonate-5PP. Decarboxylation and dehydration of mevalonate-5PP forms 
isopentenyl-PP (IPP), which converts to its isoform dimethylallyl-PP (DMAPP). DMAPP reacts with 
IPP to create geranyl-PP. Further condensation and the addition of another IPP creates farnesyl-PP. 
Condensation of 2 farnesyl-PP molecules forms squalene, which is converted to squalene epoxide 
before undergoing cyclisation to form lanosterol. Lanosterol is converted to FC, by a series of 
reactions. It is then converted to CE by ACAT2. This reaction is reversible and cholesteryl ester 
hydrolase (CEH) converts CE back to FC. The network diagram includes a nominal reaction which 
represents the putative effects of ROS on the model HMG-CoA. It also includes antioxidant levels 
which influence ROS levels. 
 
Figure 1. Network diagram of the model. The systems biology graphical notation network (SBGN) 
diagram comprises of key elements of the cholesterol biosynthesis pathway, and includes reactions 
which represent the synthesis, degradation, and regulation of hepatic LDL receptors (LDLrs). Finally, 
it incorporates reactions which depict the effects of aging on cholesterol homeostasis. Round arrow 
heads represent the target of a catalytic enzyme. Arrows represent flux. The mathematical symbol for 
an empty set represents a synthesis or sink reaction. All of these reactions are described in detail in 
the main body of the text. Hatched process nodes represent omitted processes. 
2.2. Model Analysis 
Values for kinetic parameters are contained in the Supplementary File S5. Many experimental 
values derived from the literature had to be adjusted to enable the model to enter steady state. The 
initial value references are also provided in Supplementary File S5. When this was done, COPASI 
Figure 1. Network diagram of the model. The systems biology graphical notation network (SBGN)
diagram comprises of key elements f the cholesterol biosynthesis pathway, and i cludes reactions
which represent the synthesis, degradation, and r gulati n of patic LDL receptors (LDLrs). Finally,
it incorporates reactio s which depict the effects of aging n cholesterol homeostasis. Round arrow
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an empty set represents a synthesis or si k reaction. All of th reactions are described in detail in the
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2.2. Model Analysis
Values for kinetic parameters are contained in the Supplementary File S5. Many experimental
values derived from the literature had to be adjusted to enable the model to enter steady state. The initial
value references are also provided in Supplementary File S5. When this was done, COPASI identified
a steady state which was asymptotically stable. Figure S1 in Supplementary File S2 illustrates model
variables reaching the steady state. Once it was clear the model entered a steady state, a metabolic
control analysis (MCA) was conducted [98]. MCA is a computational procedure which investigates the
regulation and control of metabolic pathways [99]. It focuses on the elements which impact the flux of
biochemical reaction networks. Once a model steady state is determined, an MCA can be conducted to
quantify the extent to which metabolite steady-state concentrations depend on the velocity of certain
reactions, or the concentration of particular variables. Thus, the MCA was completed in order to
determine the effect changing different reactions had on steady state. There are two kinds of control
coefficients: (1) the flux control coefficients and (2) the concentration control coefficients. A flux control
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The greater the control coefficients, the greater the control species or parameter has over a particular
variable. Thus, the goal was to use this technique as a means of determining the sensitivity of the model.
It is important to note control coefficients may be negative or positive. If a value is negative it means
that if the concentration of a particular species is increased, it will reduce the flux of a particular reaction.
The MCA was conducted in COPASI by selecting the following: “Tasks” - > “Metabolic Control
Analysis”- > “Run”. An output file was generated which provided the results of the analysis.
Supplementary File S2, which contains Tables S2 and S3, provides the full results of the MCA.
2.3. Hypothesis Exploration
The hypothesis outlined in the introduction was tested. To do this we examined if an increase
in HMGCR activity influenced hepatic cholesterol and LDL-C levels. The baseline Vmax for R4 was
1.43 µMoles/min, and it was necessary to increase this value to investigate the hypothesis. To do this,
a parameter scan was conducted in COPASI, with integers between 1 and 10 analysed. The parameter
scan in COPASI was conducted as follows: “Tasks”->“Parameter Scan” - > “create”. Next “Reactions”
was selected and then “Reaction Parameters”. The parameter to be scanned was selected, and “OK”
was clicked resulting in a scan window appearing. In the “Intervals” box, a “min” and “max” for
the scan was set and “Run” was selected to conduct the scan. Results were recorded at 3000 min
(50 h), as a recent in vitro study indicated ROS increase cholesterol synthesis within this time period.
Specifically, Seo et al. (2019) demonstrated that treating HepG2 cells with 500 µM H2O2 results in
a significant increase in SREBP2, HMGCR and intracellular cholesterol levels [55].
The next aspect of the hypothesis which was examined, centred on the impact of a decline in ACAT2
with age. To investigate if a reduction in ACAT2 impacted cholesterol homeostasis, a parameter scan
of the Vmax for R15 was conducted. As the baseline Vmax value was 0.04 µMoles/min, values between
0.01 and 0.06 µMoles/min were scanned using a step size of 0.01 and results were recorded at 3000 min.
It was important to determine the combined effect of these age-related changes. A parameter scan
was conducted for the two parameters simultaneously. The Vmax for R4 was scanned between 1 and
5 µMoles/min (integers). The Vmax for R15 was scanned at 5 points between 0.01 and 0.05 µMoles/min.
Results were recorded at 3000 min.
Based on the results of the MCA, it was found that reaction fluxes and species were most sensitive
to perturbations in R1, acetyl CoA synthesis. This was considered an interesting finding because it is
known that acetyl CoA can change significantly in response to a variety of pathological conditions [101].
Given that cholesterol is generated from acetyl CoA this had important implications for testing our
hypothesis because increased acetyl CoA levels could be the key driver of an increase in hepatic FC
rather than an increase in HMGCR activity. In fact, Seo et al. (2019) also found that acetyl CoA increased
significantly when the primary hepatocyte cells HepG2 were treated with ROS. It was suggested that
the results support the idea that ROS play an important role in perturbing cholesterol metabolism and
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consequently contribute to the accumulation of cholesterol hepatically during aging. Therefore, it was
deemed cogent to explore in greater depth the effect of an increase in acetyl CoA synthesis has on
the system.
To replicate an increase in acetyl CoA in a manner comparable to in vivo experimental work,
the findings of Perry et al. (2017) were utilised [102]. Perry et al. (2017) outlined the effect of 3
conditions on male rat acetyl CoA levels: namely (1) insulin resistance, induced via a high fat diet,
(2) high fat diet and T2DM, induced through the administration of 80 mg/kg nicotinamide followed
by a low dose (40 mg/kg) of streptozotocin which resulted in whole-body insulin resistance and
modest insulinopenia, and (3) T1DM, induced by the administration of 65 mg/kg streptozotocin.
The authors reported a ~15%, ~75% and ~100% increase in acetyl CoA when compared to control
animals. Therefore, the rate constant K1 for acetyl CoA synthesis was increased from 0.1 to 0.115,
0.175 and 0.2 respectively. Firstly, this simulation was conducted using the baseline age of the model.
Secondly, the effect of increased acetyl CoA synthesis was investigated when aging was also simulated.
To mimic the aging effect, the Vmax for R4 was doubled to 2.86 µMoles/min, while the Vmax for R15
was halved to 0.02 µMoles/min. This was to represent the ROS-induced increase in HMGCR activity
and the decline in ACAT2 activity. Results were recorded at 3000 min.
3. Results
3.1. The ROS and HMG-CoA Reductase Hypothesis
As outlined above experimental findings suggest ROS increases the activity of HMGCR.
The mechanism(s) responsible for this effect remain to fully delineated, however, if the activity
of HMGCR increases, it is not improbable to assume that there will be an increase in the Vmax of this
enzyme [103]. Thus, using these in silico experiments, the effect of increasing ROS levels was modelled
by elevating the Vmax of HMGCR. Figure 2A illustrates that as the Vmax of HMGCR increases there is a
drop in HMG-CoA. Figure 2B shows a progressive accumulation of FC with increasing Vmax. Figure 2C
shows a very slight increase in CE as a result of this analysis. Similarly, there is a negligible increase in
LDL-C as the Vmax of HMGCR increases (Figure 2D).Biology 2020, 9, x FOR PEER REVIEW 8 of 18 
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3.2. Exploring the Effects of a Decrease in ACAT2 Activity with Age
Next the effects of reducing the activity of ACAT2 were investigated. An age-related decrease in
ACAT2 is very tentatively supported by the work of Shiomi et al. (2000) who found that homozygous
Watanabe heritable hyperlipidemic rabbits; deficient in LDLrs had decreased ACAT2 activity with
age [58]. According to our hypothesis, it is possible that a decrease in hepatic ACAT2 activity can
result in the accumulation of hepatic FC. Figure 3A reveals an increase in FC as the Vmax of ACAT2
decreases. Additionally, based on this idea there should be a corresponding decrease in CE and LDL-C
as the activity of ACAT2 decreases (Figure 3B,C). Finally, as the Vmax for ACAT2 declines there is
corresponding decrease in LDLr numbers (Figure 3D).
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3.3. ROS Combined with a Decrease in ACAT2 with Age
The next in silico experiment centred on investigating the effect of ROS in conjunction with changes
to the activity of ACAT2 (Table 2). Figure S2 in Supplementary File S2 shows how these combined
aging effects impact LDL-C levels in the model. Modulation of the Vmax for ACAT2 had a more
pronounced effect on FC, CE, LDL-C, and LDLr than perturbation of Vmax for HMGCR. Specifically,
there is a negligible increase in FC and CE as Vmax for HMGCR is increased, while a reduction in
ACAT2 has a more prominent effect in reducing CE, and elevating FC (Figure S2A,B). Additionally,
increased Vmax for HMGCR produced a minimal rise in LDL-C whilst negligibly decreasing LDLr
numbers. This was associated with the concomitant decline in LDL-C and LDLr numbers as a result of
a reduced Vmax for ACAT2 (Figure S2C,D).
Biology 2020, 9, 314 10 of 18
Table 2. The Effect of combined HMGCR and ACAT2 modulation on FC, CE, LDL-C and LDLr.
Vmax R15 Conversion of
FC to CE (µMoles/min)
Vmax R4 Mevalonate Formation (µMoles/min)
1 2 3 4 5
FC
0.01 22.1333 22.2205 22.2485 22.2623 22.2705
0.02 9.93711 9.96287 9.97106 9.97509 9.97749
0.03 4.75843 4.76165 4.76266 4.76315 4.76345
0.04 2.83914 2.8396 2.83975 2.83981 2.83985
0.05 1.99568 1.99583 1.99587 1.99589 1.9959
CE
0.01 0.084617 0.084669 0.084685 0.084693 0.084698
0.02 0.14247 0.142576 0.14261 0.142627 0.142637
0.03 0.162901 0.162953 0.162969 0.162976 0.162981
0.04 0.166003 0.166019 0.166024 0.166026 0.166028
0.05 0.166386 0.166394 0.166397 0.166398 0.166399
LDL-C
0.01 0.08454 0.084591 0.084608 0.084616 0.084621
0.02 0.14232 0.142428 0.142462 0.142479 0.142489
0.03 0.162786 0.162839 0.162855 0.162863 0.162867
0.04 0.165925 0.165941 0.165947 0.165949 0.16595
0.05 0.166317 0.166326 0.166328 0.166329 0.16633
LDLr
0.01 34,335.9 34,334 34,333.4 34,333.1 34,332.9
0.02 34,530.3 34,527 34,526 34,525.5 34,525.2
0.03 34,770.5 34,766.7 34,765.4 34,764.8 34,764.4
0.04 34,998.3 34,994.4 34,993.2 34,992.5 34,992.2
0.05 35,192 35,188.2 35,187 35,186.4 35,186
3.4. The Impact of Increasing Acetyl CoA Synthesis
Due to the sensitivity of model species and reaction fluxes to perturbations in acetyl CoA synthesis,
as outlined in the MCAs, changes to acetyl CoA synthesis were investigated. Values of 0.115, 0.175,
and 0.2 were utilised for the rate constant K1 for acetyl CoA synthesis to represent a high fat diet, T2DM,
and T1DM, respectively, as outlined by Perry et al. (2017). The baseline rate constant was assigned
a value of 0.1. By editing this rate constant, acetyl CoA increased to 57.52 µmol/µL, approximately
double the baseline acetyl CoA concentration of 32.13 µmol/µL (Figure 4A). Perturbed acetyl CoA
synthesis was simulated in the presence or absence of aging. As the rate of acetyl CoA synthesis
increases, there is a rise in FC, CE and LDL-C (Figure 4B–D). The rise in hepatic FC was greater in
the aged simulation, whilst the rise in CE and LDL-C was less pronounced when aging was less
pronounced in the aged simulation (Figure 4E).
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4. Discussion
The dysregulation of cholesterol homeostasis, which results in elevated levels of LDL-C, is directly
relevant to the pathogenesis of CVD [104]. Demographically it is well recognised that LDL-C levels rise
with age until middle age in both males and females. Paradoxically, from a demographic perspective
a decline in LDL-C from the midpoint of life onwards has also been observed [26]. Interestingly,
when cholesterol metabolism has been examined in the oldest old, an intriguing inconsistency has been
identified. Namely, in certain studies, low levels of LDL-C have been associated with an increased
risk of mortality. In one study, which examined LDL-C levels in the oldest old, it was observed
that a higher LDL-C level was associated with lower risk of all-cause mortality [105]. Moreover,
other studies have shown that mortality from disease in old age is independent of both total cholesterol
and LDL-C [30,106]. The reason for this remains unknown. To explore this puzzle, a computational
model was used to investigate the intersection between hepatic cholesterol homeostasis and aging.
Because ROS are inevitable byproducts of oxidative phosphorylation [107], they have been linked
to the aging process [108]; therefore, it was meaningfully speculated that ROS have an impact on
cholesterol metabolism. Our reason for this idea is underpinned by recent experimental evidence which
has associated ROS with an increase in SREBP2 and HMGCR expression. This experimental work
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also demonstrated a concurrent rise in intracellular hepatic cholesterol and LDLr expression. Thus,
ROS can not only affect the cholesterol biosynthesis pathway but also the hepatic cholesterol uptake [55].
The model was used to explore these experimental findings and our hypothesis by examining changes
to HMGCR. The model responded to an increase in the Vmax for HMGCR with a decline in LDLr.
While this is biologically intuitive, this result differs from those found experimentally. This can be
explained as HMGCR was investigated as a proxy for ROS, and ROS itself was not the investigated
variable. In agreement with Seo et al. (2019), the model indicated that increased HMGCR activity
resulted in elevated hepatic FC. Moreover, as the Vmax of HMGCR increased, there was a marginal rise
in the amount of cellular CE. These small changes are perhaps unsurprising because we and others have
previously shown that there is an inherent robustness associated with cholesterol biosynthesis [83–85].
Although these increases were not overly significant and are in the main qualitative, they add some
weight to the premise that if ROS augment HMGCR activity, there will be a potential increase FC.
Perhaps more expectantly there was an increase in the concentration of LDL-C due to this perturbation.
The model was also used to investigate if an age-related decrease in hepatic ACAT2 activity
can contribute to a reduction in plasma LDL-C levels. The rationale underpinning this idea is that
hepatic ACAT2 catalyses the synthesis of CE available for secretion into nascent VLDL. Therefore,
we hypothesised that this would lead to a concomitant decrease in plasma LDL-C, and a corresponding
rise in hepatic FC. This is biologically possible because this phenomenon has been observed
experimentally in older rabbits [58]. When this intervention was applied to the model intracellular
FC increased, CE decreased and LDL-C decreased. Next the combined effects of both ROS and
ACAT2 were investigated. This in silico experiment was conducted to investigate the cornerstone
of our hypothesis; namely that these changes can account for the observation that low levels of
LDL-C are associated with an increased risk of mortality in the oldest old [104]. It was found that
the effects of ROS on the system were negligible, however, and significantly for our hypothesis it
was found that as the activity of ACAT2 decreased, there was a concomitant decrease in plasma
LDL-C. Thus, the model suggests a decrease in ACAT2 with age could contribute to a reduction in
LDL-C, and presents a mechanistic explanation as to why low LDL-C have been observed in the oldest
old [104]. This change also elicited an increase in FC. A build up in FC has cytotoxic implications
because burgeoning clinical and experimental data suggest hepatic FC accumulation is directly relevant
to the aetiology of NAFLD [109]. This finding is, to an extent, at odds with some recent experimental
work which has suggested that the nonselective inhibition of ACAT2 could be a worthwhile way to
treat hypercholesterolemia in humans [110]. This concept is largely fuelled by studies which have
shown that ACAT2-deficient mice, when compared to wild type mice, have reduced hepatic CE and
are protected against diet-induced atherosclerosis [111]. These experimental findings are intriguing
and could be accounted for by inhibition of hepatic ACAT2 precipitating the decreased production
of atherogenic apoB-containing lipoproteins, or inhibition of intestinal ACAT2 reducing cholesterol
absorption [112].
The model also investigated the effect of increased flux of acetyl CoA. From a baseline value of
0.1, the rate constant for acetyl CoA synthesis was increased to 1.115, 1.175 and 0.2 to represent a high
fat diet, poorly controlled T2DM and T1DM, respectively, as outlined by Perry et al. (2017). Model
simulations revealed that elevated acetyl CoA synthesis were associated with an increase in LDL-C,
FC, and CE and a decline in LDLr. Experimentally it has been shown that high fat diets are associated
with hepatic fat accumulation. Accumulation of fat within the liver has been linked to an increase in
PCSK9, an enzyme responsible for the degradation of LDLr. This resultant decline in cell-surface LDLr
expression then impacts the rate of LDL-C clearance and LDL-C residence time, and is associated with
a rise in LDL-C [113]. Interestingly, our model indicates that the changes outlined above are modulated
by the aging process. The aged model was associated with greater hepatic FC and reduced plasma
LDL-C accumulation. This can in part be explained by the hypothesis outlined.
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5. Conclusions
To conclude, the model suggests that an increase in the activity of HMGCR does not have as
significant an impact on cholesterol homeostasis as a decrease in hepatic ACAT2 activity. A decrease
in the activity of hepatic ACAT2 raises hepatic free cholesterol (FC) and decreases LDL-C levels.
The model also revealed that increased levels of acetyl CoA, which are linked with a high fat diet,
are associated with increased LDL-C, FC and CE, in addition to reduced LDLr. Combining the
effects of aging with increased acetyl CoA synthesis resulted in lower LDL-C which was associated
with greater accumulation of hepatic FC. Taken together this has crucial implications for healthspan
because emerging experimental and clinical data suggest hepatic FC accumulation is relevant to the
pathogenesis of non-alcoholic fatty liver disease (NAFLD), which is associated with an increased risk
of CVD. This pathophysiological change could in part help to explain the phenomenon of increased
mortality associated with low levels of LDL-C, which have been observed in certain studies involving
the oldest old (≥85 years).
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